1. COMPARATIVE STUDY OF ORMELOXIFENE AND MEDROXYPROGESTERENE ACETATE IN ABNORMAL UTERINE BLEEDING.

2. ABSTRACT; The purpose of this study was to compare the effects of ormeloxifene with medroxyprogesterene acetate in patients with abnormal uterine bleeding.

3. MATERIAL AND METHODS ; 440 patients were divided into two groups, in GROUP A, ormeloxifene was given at the dosage of 60 mg twice a week for 3 months followed by 60 mg once a week for 1 month. In GROUP B,medroxyprogestrene acetate was given at the dosage of 10 mg twice a day from day 5 to 25 of the menstrual cycle. At followups: PBAC SCORE. ENDOMETRIAL THICKENESS BY USG. HEMOGLOBIN LEVELS AND THE SIDEEFECTS OF THE DRUG THERAPY.

4. RESULTS: 240 patients in GROUPA,200 PATIENTS IN GROUP B Reduction in PBAC SCORE was 79.4% in GROUP A AND 75% IN GROUP B after 4 months of treatment. The mean duration bleeding reduced to 4.8 from 9 in GROUP A and 5 from 8.7 in GROUP B. Mean hemoglobin was increased from 8.6 to 9.8 gms % in GROUP A and from 8.7 to 9.9 gms % in GROUP B. Endometrial thickness from 7.7 mm to 6.8 mm in GROUP A and from 7.4 mm to 6.9 in GROUP B.

5. CONCLUSION: We conclude from this study that ormeloxifene should be considered the first choice In the management of of AUB,especially in the perimenopausal age group where amennorehea is acceptable.